Tumor-infiltrating lymphocytes

BIOLOGICAL2 trials

Sponsors

University Health Network, Toronto, NeogenTC

Conditions

Advanced Breast CancerAdvanced Lung CancerMetastatic, Stage III or Stage IV, Melanoma

Phase 1

TIL Therapy for Patients With Advanced Solid Tumors

Not yet recruitingNCT06107894

NeogenTCAdvanced Breast Cancer, Advanced Lung Cancer

Start: 2024-01-31End: 2026-05-31Target: 12Updated: 2023-10-30

Phase 2

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

CompletedNCT01883323

University Health Network, TorontoMetastatic, Stage III or Stage IV, Melanoma

Start: 2013-06-30End: 2018-04-30Updated: 2019-11-08

Related Papers

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

Cancer Immunology Immunotherapy2019-02-11132 citations